Terms: = Kidney tumors AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Clinical Outcome
22 results:
1. clinical outcome of high-dose bolus intravenous interleukin-2 with a modified administration schedule for Asian patients with metastatic renal cell carcinoma.
Lee JY; Song C; Hong BS; Hong JH; Ahn H; Lee JL
Cancer Chemother Pharmacol; 2017 Jan; 79(1):173-180. PubMed ID: 28011979
[TBL] [Abstract] [Full Text] [Related]
2. FCGR Polymorphisms Influence Response to il2 in Metastatic Renal Cell Carcinoma.
Erbe AK; Wang W; Goldberg J; Gallenberger M; Kim K; Carmichael L; Hess D; Mendonca EA; Song Y; Hank JA; Cheng SC; Signoretti S; Atkins M; Carlson A; Mier JW; Panka DJ; McDermott DF; Sondel PM
Clin Cancer Res; 2017 May; 23(9):2159-2168. PubMed ID: 27742794
[No Abstract] [Full Text] [Related]
3. Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose il2.
Wang W; Erbe AK; Gallenberger M; Kim K; Carmichael L; Hess D; Mendonca EA; Song Y; Hank JA; Cheng SC; Signoretti S; Atkins M; Carlson A; Weiss JM; Mier J; Panka D; McDermott DF; Sondel PM
Cancer Immunol Immunother; 2016 Dec; 65(12):1523-1532. PubMed ID: 27695964
[TBL] [Abstract] [Full Text] [Related]
4. Immunotherapy of metastatic renal cell carcinoma.
McDermott DF
Cancer; 2009 May; 115(10 Suppl):2298-305. PubMed ID: 19402060
[TBL] [Abstract] [Full Text] [Related]
5. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial.
Olioso P; Giancola R; Di Riti M; Contento A; Accorsi P; Iacone A
Hematol Oncol; 2009 Sep; 27(3):130-9. PubMed ID: 19294626
[TBL] [Abstract] [Full Text] [Related]
6. Immunotherapy of metastatic renal cell carcinoma.
McDermott DF; Atkins MB
Cancer J; 2008; 14(5):320-4. PubMed ID: 18836337
[TBL] [Abstract] [Full Text] [Related]
7. clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract] [Full Text] [Related]
8. clinical outcome and prognostic survival factors in patients with advanced renal cell carcinoma treated with very low-dose interleukin-2, interferon-alpha, and tegafur-uracil: a single-institution experience.
Kobayashi M; Ikeda H; Nukui A; Suzuki K; Sugaya Y; Yuzawa M; Morita T
Int J Clin Oncol; 2008 Jun; 13(3):257-62. PubMed ID: 18553237
[TBL] [Abstract] [Full Text] [Related]
9. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma.
Bleumer I; Oosterwijk E; Oosterwijk-Wakka JC; Völler MC; Melchior S; Warnaar SO; Mala C; Beck J; Mulders PF
J Urol; 2006 Jan; 175(1):57-62. PubMed ID: 16406869
[TBL] [Abstract] [Full Text] [Related]
10. Emerging drugs for renal cell carcinoma.
Shaheen PE; Bukowski RM
Expert Opin Emerg Drugs; 2005 Nov; 10(4):773-95. PubMed ID: 16262562
[TBL] [Abstract] [Full Text] [Related]
11. clinical outcome of combined immunotherapy with low-dose interleukin-2 and interferon-alpha for Japanese patients with metastatic renal cell carcinoma who had undergone radical nephrectomy: a preliminary report.
Miyake H; Hara I; Sakai I; Harada K; Inoue TA; Eto H; Takechi Y; Fujisawa M
Int J Clin Oncol; 2005 Oct; 10(5):338-41. PubMed ID: 16247661
[TBL] [Abstract] [Full Text] [Related]
12. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.
Atkins M; Regan M; McDermott D; Mier J; Stanbridge E; Youmans A; Febbo P; Upton M; Lechpammer M; Signoretti S
Clin Cancer Res; 2005 May; 11(10):3714-21. PubMed ID: 15897568
[TBL] [Abstract] [Full Text] [Related]
13. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
[TBL] [Abstract] [Full Text] [Related]
14. Depletion of normal B cells with rituximab as an adjunct to il-2 therapy for renal cell carcinoma and melanoma.
Aklilu M; Stadler WM; Markiewicz M; Vogelzang NJ; Mahowald M; Johnson M; Gajewski TF
Ann Oncol; 2004 Jul; 15(7):1109-14. PubMed ID: 15205206
[TBL] [Abstract] [Full Text] [Related]
15. clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells.
Harlin H; Artz AS; Mahowald M; Rini BI; Zimmerman T; Vogelzang NJ; Gajewski TF
Bone Marrow Transplant; 2004 Mar; 33(5):491-7. PubMed ID: 14716341
[TBL] [Abstract] [Full Text] [Related]
16. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.
Schmidt-Wolf IG; Finke S; Trojaneck B; Denkena A; Lefterova P; Schwella N; Heuft HG; Prange G; Korte M; Takeya M; Dorbic T; Neubauer A; Wittig B; Huhn D
Br J Cancer; 1999 Nov; 81(6):1009-16. PubMed ID: 10576658
[TBL] [Abstract] [Full Text] [Related]
17. Immunological changes in peripheral blood mononuclear cells of patients with metastatic renal cell carcinoma after low doses of subcutaneous immunotherapy with IFN-alpha-2b and il-2.
Moltó L; Carballido J; Manzano L; Martinez-Martin B; Esquivel F; Chafer J; Olivier C; Alvarez-Mon M
J Immunother; 1999 May; 22(3):260-7. PubMed ID: 10335486
[TBL] [Abstract] [Full Text] [Related]
18. The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b.
Tsavaris N; Baxevanis C; Kosmidis P; Papamichael M
Cancer Immunol Immunother; 1996 Oct; 43(2):94-102. PubMed ID: 8954143
[TBL] [Abstract] [Full Text] [Related]
19. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.
Belldegrun A; Tso CL; Kaboo R; Pang S; Pierce W; deKernion JB; Figlin R
J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):149-61. PubMed ID: 8732698
[TBL] [Abstract] [Full Text] [Related]
20. Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, il-2 and alpha-IFN.
Wersäll P; Mellstedt H
Med Oncol; 1995 Jun; 12(2):69-77. PubMed ID: 8535664
[TBL] [Abstract] [Full Text] [Related]
[Next]
